1. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008;168(14):1585-91. [
DOI:10.1001/archinte.168.14.1585] [
PMID]
2. Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis 2013;13(1):1. [
DOI:10.1186/1471-2334-13-252] [
PMID] [
PMCID]
3. FDA. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment. Food and Drug Administration. Silver Spring, Maryland, 2013 October 23;78, No. 205. [
URL]
4. Rajan S. Skin and soft-tissue infections: classifying and treating a spectrum. Cleve Clin J Med 2012; 79: 57-66. [
DOI:10.3949/ccjm.79a.11044] [
PMID]
5. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 79(1):57. [
PMID] [
PMCID]
6. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007; 357(4):380-90. [
DOI:10.1056/NEJMcp070747] [
PMID]
7. Dryden M. Complicated skin and soft tissue infection. J Antimicrob Chemother 2016; 65:35-44. [
DOI:10.1093/jac/dkq302] [
PMID]
8. Wilcox MH. The tide of antimicrobial resistance and selection. Int J Antimicrob Agents. 2009; 34:6-10. [
DOI:10.1016/S0924-8579(09)70550-3]
9. Nathwani D. New antibiotics for the management of complicated skin and soft tissue infections: are they any better? Int J Antimicrob Agents 2009;34:24-9. [
DOI:10.1016/S0924-8579(09)70546-1]
10. Cardona AF, Wilson SE. Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment. Clin Infect Dis 2015; 61: 69-78 [
DOI:10.1093/cid/civ528] [
PMID]
11. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59(2): 10-52.
https://doi.org/10.1093/cid/ciu296 [
DOI:10.1093/cid/ciu444] [
PMID]
12. Klinker KP, Borgert SJ. Beyond vancomycin: the tail of the lipoglycopeptides. Clin Ther 2015; 37: 2619-2636. [
DOI:10.1016/j.clinthera.2015.11.007] [
PMID]
13. Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005;49:770-2. [
DOI:10.1128/AAC.49.2.770-772.2005] [
PMID] [
PMCID]
14. Saravolatz LD, Stein GE. Oritavancin: a long-half-life lipoglycopeptide. Clin Infect Dis 2015; 61: 6627-32. [
DOI:10.1093/cid/civ311] [
PMID]
15. Agarwal R, Bartsch SM, Kelly BJ, Prewitt M, Liu Y, Chen Y, Umscheid CA. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect 2018; 24(4):361-8 [
DOI:10.1016/j.cmi.2017.08.028] [
PMID] [
PMCID]
16. Julian F. Guest, Jaime Esteban, Anton G. Manganelli, Andrea Novelli, Giuliano Rizzardini, Miquel Serra. Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis. PLoS ONE 2017; 12(11):0187792. [
DOI:10.1371/journal.pone.0187792] [
PMID] [
PMCID]
17. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 2007; 7(1):1-6 [
DOI:10.1186/1472-6947-7-16] [
PMID] [
PMCID]
18. Salanti G. Indirect and mixed-treatment comparison, network, or multiple treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012; 3: 80-97. [
DOI:10.1002/jrsm.1037] [
PMID]
19. A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159(2):130-7. [
DOI:10.7326/0003-4819-159-2-201307160-00008] [
PMID]
20. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019 Sep 23. [
DOI:10.1002/9781119536604]
21. Higgins J, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. [
DOI:10.1136/bmj.327.7414.557] [
PMID] [
PMCID]
22. Stevens D, Smith CT, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2000; 44(12):3408-13. [
DOI:10.1128/AAC.44.12.3408-3413.2000] [
PMID] [
PMCID]
23. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in the treatmentof complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6 [
DOI:10.1128/AAC.49.6.2260-2266.2005] [
PMID] [
PMCID]
24. Scott LJ. Dalbavancin: a review in acute bacterial skin and skin structure infections. Drugs 2015;75(11):1281-91. [
DOI:10.1007/s40265-015-0430-x] [
PMID]
25. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. N Engl J Med 2014; 370(23):2180-90. [
DOI:10.1056/NEJMoa1310422] [
PMID]
26. Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-Dose Oritavancin Versus 7-10 Days of Vancomycin in the Treatment of Gram-PositiveAcute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study. Clin Infect Dis 2015;60(2):254-62. [
DOI:10.1093/cid/ciu778] [
PMID]
27. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Inf Dis 2005;41(10):1407-15. [
DOI:10.1086/497271] [
PMID]
28. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Inf Dis 2005;40(11):1601-7. [
DOI:10.1086/429914] [
PMID]
29. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-7. [
DOI:10.1128/AAC.50.3.862-867.2006] [
PMID] [
PMCID]
30. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin structure infections caused by Gram-positive organisms. Clin Infect Dis 2008; 46(11):1683-93. [
DOI:10.1086/587896] [
PMID]
31. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistantStaphylococcus aureus in Japan. J Antimicrob Chemother 2007; 60(1):1361-9. [
DOI:10.1093/jac/dkm369] [
PMID]
32. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Inf Dis 2009;48(2):203-12. [
DOI:10.1086/595686] [
PMID]
33. Lin DF, Zhang YY, Wu JF, Wang F, Zheng JC, Miao JZ, et al. Linezolid for the treatment of infections caused by gram-positive pathogens in China. Int J Antimicrob Agents 2008;32(3):241-9. [
DOI:10.1016/j.ijantimicag.2008.04.004] [
PMID]
34. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, noninferioritytrial. Lancet Infect Dis 2014; 14(8):696-705. [
DOI:10.1016/S1473-3099(14)70737-6]
35. Moran GJ, De Anda C, Das AF, Green S, Mehra P, Prokocimer P. Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials. Infect Dis Ther 2018; 7(4):509-22 [
DOI:10.1007/s40121-018-0211-4] [
PMID] [
PMCID]
36. O'Riordan W, McManus A, Teras J, Poromanski I, Cruz-Saldariagga M, Quintas M, et.al. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin-Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study. Clin Infect Dis 2018;67(5):657-66. [
DOI:10.1093/cid/ciy165] [
PMID] [
PMCID]
37. Prokocimer P, De AC, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections. The ESTABLISH-1 randomized trial. JAMA 2013;309(6):559-69 [
DOI:10.1001/jama.2013.241] [
PMID]
38. Covington P, Davenport JM, Andrae D, O'Riordan W, Liverman L, McIntyre G, et al. Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, a Novel Fluoroquinolone, Compared with Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infection. Antimicrob Agents Chemother 2011;55(12):5790-7. [
DOI:10.1128/AAC.05044-11] [
PMID] [
PMCID]
39. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. New Eng J Med 2014;370(23):2180-90. [
DOI:10.1056/NEJMoa1310422] [
PMID]
40. Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, et al. A Randomized, Double-Blind Phase 2 Study Comparing the Efficacy and Safety of an Oral Fusidic Acid Loading-Dose Regimen to Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis 2011; 52:520-6. [
DOI:10.1093/cid/cir167] [
PMID]
41. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49(11):4658-66. [
DOI:10.1128/AAC.49.11.4658-4666.2005] [
PMID] [
PMCID]
42. Chuang YC, Chang CM, Aradhya S, Nagari B, Pai V, Dartois N, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. J Microbiol Immunol Infect 2011; 44(2):116-24. [
DOI:10.1016/j.jmii.2010.04.002] [
PMID]
43. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin-Structure Infections: Results of 2 Double-Blind Phase 3 Comparison Studies with Vancomycin-Aztreonam. Clin Infect Dis 2005;41(5):341-53 [
DOI:10.1086/431675] [
PMID]
44. Teras J, Gardovskis J, Vaasna T, Kupcs U, Pupelis G, Dukart G, et al. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections-a European perspective. J Chemother 2008; 20(1):20-7. [
DOI:10.1179/joc.2008.20.Supplement-1.20] [
PMID]
45. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9:251-61. [
DOI:10.1016/j.ijid.2005.05.003] [
PMID]
46. Corey CA. 1: the first Phase III, randomized, double-blind study evaluating cefazoline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65:41-51. [
DOI:10.1093/jac/dkq254] [
PMID]
47. Wilcox CA. 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections J Antimicrob Chemother 2010; 65:53-65. [
DOI:10.1093/jac/dkq256] [
PMID]
48. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51(10):3612-6. [
DOI:10.1128/AAC.00590-07] [
PMID] [
PMCID]
49. O'Riordan W, McManus A, Teras J, Poromanski I, Cruz-Saldariagga M, Quintas M, et al. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study. Clin Inf Dis 2018;67(5):657-66. [
DOI:10.1093/cid/ciy165] [
PMID] [
PMCID]
50. Pullman J, Gardovskis J, Farley B, Sun E, Quintas M, Lawrence L, Ling R, Cammarata S. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother 2017;72(12):3471-80. [
DOI:10.1093/jac/dkx329] [
PMID] [
PMCID]
51. Kingsley J, Mehra P, Lawrence L E, Henry E, Duffy E, Cammarata S K, et al. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother 2016;71:821-9. [
DOI:10.1093/jac/dkv411] [
PMID] [
PMCID]
52. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et. al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162(11): 777-84. [
DOI:10.7326/M14-2385] [
PMID]
53. Annemans L, Fleurence R, Jansen JP, Devine B, Itzler R, Barrett A et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making : report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices : part 1. Value Health 2011;14(4):417-28. [
DOI:10.1016/j.jval.2011.04.002] [
PMID]
54. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14(4):429-37. [
DOI:10.1016/j.jval.2011.01.011] [
PMID]
55. Charlton V. NICE and fair? Health technology assessment policy under the UK's National Institute for Health and Care Excellence, 1999-2018. Health Care Analysis 2020;28(3):193-227. [
DOI:10.1007/s10728-019-00381-x] [
PMID] [
PMCID]
56. Garnock-Jones KP. Single-dose dalbavancin: a review in acute bacterial skin and skin structure infections. Drugs 2017;77(1):75-83. [
DOI:10.1007/s40265-016-0666-0] [
PMID]
57. Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis 2016; 62(5):545-51. [
DOI:10.1093/cid/civ982] [
PMID] [
PMCID]
58. Polyzos KA, Mavros MN, Vardakas KZ, Makris MC, Rafailidis PI, Falagas ME. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One 2012; 7:41870. [
DOI:10.1371/journal.pone.0041870] [
PMID] [
PMCID]
59. Chuan J, Zhang Y, He Xi, Zhu Y, Zhong L, Yu D, et al. Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer? Front Pharmacol 2016; 7:330. [
DOI:10.3389/fphar.2016.00330] [
PMID] [
PMCID]
60. Ying Zhang et al. Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated pneumonia. Antimicrob Resist Infect Control 2019; 8(1):1. [
DOI:10.1186/s13756-019-0518-2] [
PMID] [
PMCID]
61. Yue J, Dong BR, Yang M, Chen X, Wu T, Liu GJ. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2016; 9(1):103-66. [
DOI:10.1002/14651858.CD008056.pub3] [
PMID]
62. Nathwani D, Eckmann C, Lawson W, Stephens JM, Macahilig C, Solem CT, et al. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin Microbiol Infect 2014;20(10):993-1000. [
DOI:10.1111/1469-0691.12632] [
PMID]
63. Klinker KP, Borgert SJ. Beyond vancomycin: the tail of the lipoglycopeptides. Clin Ther 2015;37(12):2619-36. [
DOI:10.1016/j.clinthera.2015.11.007] [
PMID]
64. Saravolatz LD, Stein GE. Oritavancin: a long-half-life lipoglycopeptide. Clin Infect Dis 2015; 61(4):627-32. [
DOI:10.1093/cid/civ311] [
PMID]